Bio View (XTAE:BIOV) ROC % : -37.84% (As of Dec. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Bio View ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Bio View's annualized return on capital (ROC %) for the quarter that ended in Dec. 2024 was -37.84%.

As of today (2025-04-04), Bio View's WACC % is 10.14%. Bio View's ROC % is -15.37% (calculated using TTM income statement data). Bio View earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Bio View ROC % Historical Data

The historical data trend for Bio View's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio View ROC % Chart

Bio View Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROC %

Get a 7-Day Free Trial

10.05

16.58

0.35

1.42

-14.85

Bio View Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROC %	Get a 7-Day Free Trial															7.81	9.13	-5.15	8.44	-37.84

Bio View ROC % Calculation

Bio View's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2024 is calculated as:

	ROC % (A: Dec. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2023 )	+	Invested Capital (A: Dec. 2024 ))	/ count )
=	-2.972 * ( 1 - -10.19% )	/	( (22.184	+	21.928)	/ 2 )
=	-3.2748468	/	22.056
=	-14.85 %

where

	Invested Capital		(A: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	41.955	-	2.657	-	( 17.114	-	max(0, 11.909	-	31.932	+	17.114	))
=	22.184

	Invested Capital		(A: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	33.623	-	0.753	-	( 10.942	-	max(0, 9.808	-	24.578	+	10.942	))
=	21.928

Bio View's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2024 is calculated as:

	ROC % (Q: Dec. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Dec. 2024 ))	/ count )
=	-8.098 * ( 1 - 2.48% )	/	( (19.816	+	21.928)	/ 2 )
=	-7.8971696	/	20.872
=	-37.84 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	42.678	-	6.064	-	( 16.798	-	max(0, 11.7	-	33.778	+	16.798	))
=	19.816

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	33.623	-	0.753	-	( 10.942	-	max(0, 9.808	-	24.578	+	10.942	))
=	21.928

Note: The Operating Income data used here is two times the semi-annual (Dec. 2024) data.

Bio View (XTAE:BIOV) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Bio View's WACC % is 10.14%. Bio View's ROC % is -15.37% (calculated using TTM income statement data). Bio View earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Bio View ROC % Related Terms

Thank you for viewing the detailed overview of Bio View's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio View Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio View Ltd (XTAE:BIOV) » Definitions » ROC %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 Pekeris Street, Rehovot, ISR, 7670203

Website

http://www.bioview.co.il

Bio View Ltd is an Israel based company engaged in the research, development, manufacture, marketing, and sale of computerized systems for identification of rate cells and test for detection of cancer. It manufactures and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, pathology clinical and research laboratories. Geographically, the group has its business presence in Israel, USA, and other countries, of which majority of the revenue is derived from the USA.

Bio View Headlines

No Headlines